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Between 5% and 10% of people with psychosis will die by 
suicide, a rate which is 20–75 times higher than the general 
population. This risk is even greater in those not taking 
antipsychotic medication. We examined whether negative 
appraisals of psychotic experiences and negative metacog-
nitive beliefs about losing mental control mediated a rela-
tionship between psychotic symptoms and suicidal ideation 
in this group. Participants were diagnosed with schizo-
phrenia spectrum disorders, antipsychotic-free for 6 months 
at baseline, and were participating in an 18-month random-
ized controlled trial of cognitive therapy vs treatment as 
usual. We conducted a series of mediation analyses with 
bootstrapping on baseline (N = 68), follow-up data (9–18 
mo; n = 49), and longitudinal data (n = 47). Concurrent ge-
neral symptoms were directly associated with suicidal ide-
ation at baseline, and concurrent negative symptoms were 
directly associated with suicidal ideation at 9–18 months. 
Concurrent positive, negative, general, and overall symp-
toms were each indirectly associated with suicidal idea-
tion via negative appraisals and/or negative metacognitive 
beliefs, at baseline and 9–18 months, except for negative 
symptoms at baseline. Controlling for baseline suicidal ide-
ation and treatment allocation, baseline general symptoms 
were indirectly associated with later suicidal ideation, via 
baseline negative appraisals and negative metacognitive 
beliefs. Baseline negative metacognitive beliefs also had a 
direct association with later suicidal ideation. These find-
ings suggest the clinical assessment of suicidal ideation in 
psychosis may be enhanced by considering metacognitive 
beliefs about the probability and consequences of losing 
mental control.
Key words:  psychosis/schizophrenia/suicide/
antipsychotic medication/appraisals/metacognitive 
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Introduction
Estimates of suicide rates among individuals diagnosed 
with schizophrenia spectrum disorders range from 5% to 
10%, making it a leading cause of premature death in this 
population.1–3 Nonuse of antipsychotics is thought to in-
crease this risk further, with one large observational study 
reporting a 37 times greater risk of suicide in inpatients 
who were not taking antipsychotics.4 Given antipsychot-
ics have their strongest effects on the positive symptoms 
of psychosis,5 it is plausible that individuals not taking 
this medication may have greater positive symptom se-
verity than those who do—and that this accounts for 
their increased suicide risk.
However, the evidence on the contribution of positive 
symptoms to suicide risk remains unclear. One meta-
analysis suggested they were associated with a lower 
risk;3 one found no association6 whereas another found 
they were associated with a higher risk.7 Although this 
inconsistency may reflect methodological differences, the 
absence of a robust relationship may indicate the pres-
ence of underlying mechanisms that have yet to be fully 
accounted for. As predicted by cognitive theories,8,9 sev-
eral studies have found that the way a person interprets 
or “appraises” their psychotic experiences may be more 
important than symptom severity for predicting suicidal 
behavior.10,11 Importantly, one review found that people 
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with psychosis who die by suicide were more likely to have 
“fears of mental disintegration” than matched controls.3
This latter finding suggests “metacognition”12,13 may be 
important for understanding their suicidality. Whereas 
cognition refers to knowledge and appraisals of the exter-
nal world, metacognition refers to knowledge and beliefs 
relating to the structure and integrity of the self, and 
ones own cognitive processes. Although the distinction 
between metacognition and cognition has been debated,13 
Moritz and Lysaker13 review how it has been usefully 
applied in psychosis to understanding the psychologi-
cal mechanisms implicated in (a) awareness of cognitive 
biases,14 such as the “jumping to conclusions” bias15,16; (b) 
concepts of self  and others, including perceived self-inte-
gration17; and (c) negative metacognitive beliefs about the 
uncontrollability and danger of worry and rumination.18 
In relation to the latter, high levels of negative metacogni-
tive beliefs are associated with psychotic symptom sever-
ity and chronicity,19–22 and changing these beliefs may lead 
to improvements in psychotic symptoms.23–26 Although 
worry and rumination are associated with suicidality in 
various populations27–29 and although a cross-sectional 
study (N = 1920) found that rumination was associated 
with increased suicidality in people with schizophrenia,30 
negative metacognitive beliefs have not featured promi-
nently in theoretical accounts of their increased suicide 
risk.31
In this study, we set out to test a metacognitive model 
of suicidal ideation in this group (see figure  1).32 We 
focused on recent suicidal ideation (past 2 wk) because of 
its strong relationship to dying from suicide in psychosis 
(OR = 30, 95% CI = 12, 73)3 and we focused on those 
who have been antipsychotic-free for an extended period 
of time, because they are considered to be at particularly 
high risk of suicide.4 The model we tested is a version of 
a model of psychosis-related distress we developed for a 
recent case series of metacognitive therapy (MCT),23 but 
adapted to explain suicidality. According to this, a per-
son may have suicidal thoughts because of an increase 
in the severity and negative content of their psychotic 
symptoms, which may in turn activate cognitive apprais-
als involving defeat and hopelessness (eg, “I am powerless 
to influence or control my experiences”).11 However, the 
effect of symptoms and symptom appraisals on suicidal 
ideation will be magnified by negative “metacognitive” 
beliefs about the uncontrollability and danger of worry 
(eg, “My worrying thoughts persist, no matter how I try 
to stop them,” “My worrying could make me go mad”). 
The emergence of suicidal ideation can be conceptualized 
as not only a response to symptoms and related percep-
tions of defeat and entrapment, but also as attempts at 
cognitive control, motivated by worry about the uncon-
trollability and danger of worry itself.
To test the model, we examined whether negative cog-
nitive appraisals and negative metacognitive beliefs medi-
ate the relationship between psychotic symptoms (overall, 
positive, negative, or general) and suicidal ideation at 
baseline (mo 0)  and at follow-up (mo 9–18). We then 
examined whether their initial cognitive appraisals and 
metacognitive beliefs mediated the relationship between 
initial symptom severity and future suicidal ideation.
Methods
Study Design, Participants, and Procedures
This study is a secondary analysis of baseline and 
9–18  month data obtained from the ACTION ran-
domized controlled trial (RCT), a pilot trial designed 
to assess the effects of cognitive therapy in individuals 
with a schizophrenia spectrum diagnosis not receiving 
antipsychotic medication for at least 6  months.32 The 
trial was approved by the UK NHS National Research 
Fig. 1. Metacognitive model of suicidal ideation in psychosis.
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Ethics Service (09/H1014/53) and conducted in 2 sites 
(Manchester and Newcastle) between 2010 and 2013 (see 
protocol33 for further information).
Measures
Symptoms: Positive and Negative Syndrome Scale. The 
Positive and Negative Syndrome Scale (PANSS)34 is a 
30-item interview-based measure developed to assess 
the following symptom subscales associated with schiz-
ophrenia: General Psychopathology (16 items), Negative 
Symptom Scale (7 items), and Positive Symptom Scale 
(7 items). Symptoms in the preceding week are assessed 
using a 1- to 7-point Likert scale.
Cognitive Appraisals: Personal Beliefs About Experiences 
Questionnaire. The Personal Beliefs about Experiences 
Questionnaire (PBEQ) is a revised version of the Personal 
Beliefs about Illness Questionnaire (PBIQ),35,36 and is 
designed to measure cognitive appraisals about psy-
chotic experiences. Rating of the 13 items is on a 4-point 
Likert-type scale, which ranges from “strongly disagree” 
to “strongly agree.” Factor analysis suggests the PBEQ 
measures 3 specific domains of cognitions: Negative 
Appraisal of Experience (5 items), External Shame (2 
items), and Internal Shame/Defectiveness (6 items).37 The 
PBEQ was also shown to have adequate internal reliability 
and validity. The Negative Appraisal of Experience sub-
scale, which assesses the respondent’s negative apprais-
als and expectations of their own psychotic experiences, 
was used in this analysis. Items include “I am powerless 
to influence or control my experiences” and “My experi-
ences frighten me.”
Negative Metacognitive Beliefs: The Metacognitions 
Questionnaire-30. The Metacognitions Question-
naire-30 (MCQ-30)38 is a 30-item self-report question-
naire, which measures individual metacognitive beliefs 
and processes, grouped under 5 different subscales: posi-
tive beliefs about worrying, negative beliefs about uncon-
trollability and danger of worry, cognitive confidence, 
beliefs about the need to control thoughts, and cognitive 
self-consciousness. Items are scored on a 4-point Likert-
type scale with 1 representing “I do not agree” and 4 rep-
resenting “I agree very much.” The MCQ-30 has good 
internal consistency, validity, and reliability.38 We used 
the “Negative beliefs about uncontrollability and dan-
gerousness of thoughts” subscale in the current analy-
sis. This assesses negative metacognitive appraisals and 
expectations about worrying and thinking. Items include 
“My worrying could make me go mad” and “My worry-
ing is dangerous for me.”
The Beck Depression Inventory for Primary Care. The 
Beck Depression Inventory for Primary Care (BDI-PC)39 
is a self-report questionnaire that measures depression 
severity. In this analysis, responses to item 7 (item 9 in 
the full BDI-2) were used to measure suicidal ideation. 
This item requires participants to select which of 4 state-
ments best describe their experiences over the preceding 
2 weeks. The statements are “I don’t have any thoughts 
of killing myself” (score of 0), “I have thoughts of kill-
ing myself, but I would not carry them out” (score of 1), 
“I would like to kill myself” (score of 2), and “I would 
kill myself  if  I had the chance” (score of 3). Responses 
correlate highly with the Beck Scale of Suicidal Ideation 
(r  =  .56–.58),40 and individuals scoring ≥2 on this item 
were 6.9 times more likely to commit suicide than those 
scoring <2.41
Statistical Analyses. Mediation analyses were con-
ducted to concurrently test the direct effect of psychotic 
symptoms (overall, positive, negative, or general) on sui-
cidal ideation, and their hypothesized indirect effects 
through cognitive appraisals and metacognitive beliefs, 
at the 2 time points when we assessed each variable. To 
minimize the loss of power introduced by missing data 
at follow-up, we combined into one group those who had 
full datasets at either 9  months (n  =  39) or 18  months 
(n = 10). To assess the risk of bias introducing by miss-
ing data, we tested for differences in baseline characteris-
tics between the full baseline sample (N = 68) and those 
for whom we had full baseline and full follow-up data 
(n = 47). We also ran all baseline mediation analyses in 
both samples and covaried for the follow-up assessment 
time point (9 or 18 mo).
We tested a model whereby, after controlling for partic-
ipant differences in age, gender, years of education, group 
allocation (follow-up analysis only), and the point when 
suicidal ideation was assessed (follow-up analysis only), 
psychotic symptoms activate negative cognitive apprais-
als, which then activate negative metacognitive beliefs, 
which in turn activates greater suicidal ideation (figure 1). 
All mediation analyses were performed using Model 6 of 
the PROCESS42 macro for the IBM Statistical Package 
for Social Sciences (SPSS) (see figure  2). This macro is 
based on a logistic regression-based path analytic frame-
work and uses bootstrapping to determine the magnitude 
and significance of the direct (unmediated) and indirect 
(mediated) effects.43 Bootstrapping is a nonparametric 
approach that can be applied to smaller sample sizes and 
nonnormal data.44 All models were conducted with bias-
corrected confidence intervals based on 5000 samples. 
In line with previous studies,45–48 suicidal ideation scores 
were treated as a continuous variable in all analyses.
We used linear regression to explore the potential 
prospective association between psychotic symptoms, 
metacognitive beliefs, and suicidal ideation over time. 
This analysis focuses on the residual variance in suicidal 
ideation once baseline levels are accounted for. For the 
linear regression model, suicidal ideation at 9–18 months 
was first regressed onto symptoms (positive, negative, and 
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general) and covariates (same as 9–18 mo cross-sectional 
analysis, but with the addition of baseline suicidal ide-
ation). We then examined whether models also incorpo-
rating (a) baseline negative cognitive appraisals and (b) 
baseline negative metacognitive beliefs helped to explain 
additional variance.
We then tested whether cognitive appraisals and neg-
ative metacognitive beliefs at baseline mediated a rela-
tionship between psychotic symptoms at baseline and 
suicidal ideation at 9–18 months, using the same covari-
ates for the linear regression. For this, the baseline value 
of each symptom category was the independent variable, 
the mediating variables of interest were baseline apprais-
als and metacognitive beliefs, and the dependent variable 
was suicidal ideation at 9–18 months. We also examined 
the effect of symptom categories with and without other 
symptom categories as covariates.
For all mediation analyses, the unstandardized direct 
effect (UDE) or indirect effect (UIE), and the com-
pletely standardized indirect effects (CSE) were cal-
culated as measures of  effect size. The UDE and UIE 
represent the unit change in the dependent variable per 
unit change in the independent, whether direct (unme-
diated; UDE) or indirect (mediated; UIE). The CSE 
represents the proportion of  standard deviation change 
in the dependent variable per 1 SD unit change in the 
independent variable, occuring through change in the 
mediator. Cohen’s guidelines for interpreting standard-
ized mean differences can therefore be applied to the 
CSE to provide an approximate appraisal of  the mag-
nitude of  the dependent variable change (0.2 = small, 
0.5 = moderate, 0.8 = large),49 per a large (1 SD) change 
in the independent variable. Cohen’s criteria were also 
used to interpret correlations (0.1 = small, 0.3 = mod-
erate, 0.5 = large).
Results
Participant Characteristics
The mean age of the full sample (N  =  68) was 31 
(SD = 12.75). Just under half  (n = 31, 46%) were female 
(table  1). Overall, 60% (n  =  41) of these participants 
reported suicidal ideation at trial entry; 50% (n  =  34) 
reported having mild suicidal ideation whereas 10% 
(n = 7) reported severe to very severe ideation involving 
intent. There were no significant differences in demo-
graphics, symptom severity, suicidal ideation, negative 
cognitive appraisals, or negative metacognitive beliefs 
between the full sample, and those who provided full data 
at baseline and 9–18 months (all Ps > .1).
Correlations
No correlation was observed between suicidal ideation 
and negative symptoms at baseline, but a moderate cor-
relation (r = .30) was evident at 9–18 months (table 2). At 
baseline, moderate correlations were observed between 
suicidal ideation and positive and overall symptoms for 
the sample with 9–18-month data. These associations 
were large at 9–18 months (r =  .47–.51). Large correla-
tions (r = .43–.57) between suicidal ideation and negative 
cognitive appraisals, negative metacognitive beliefs, and 
general symptoms were also observed at both baseline 
(both samples) and 9–18 months.
Cross-sectional Analyses
Baseline. All results in the full sample (reported here) 
were replicated in those with full baseline and follow-
up data (supplementary table S1). Total symptoms were 
related to suicidal ideation through the negative cogni-
tive appraisals alone (CSE = 0.13, 95% CI = 0.04, 0.25) 
Fig. 2. General mediation model tested (ie, PROCESS Model 6).
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Table 1. Participant Characteristics
All 9–18 mo completers
Variable 0 mo (N = 68) 0 mo (n = 47–49) 9–18 mo (n = 49)
Age, mean (SD), y 31.28 (12.75) 29.92 (11.18)
Gender (female), n (%) 31 (46) 23 (47)
Years of education, mean (SD) 12.59 (3.03) 12.31 (2.86)
MCQ-30: “Negative Beliefs About Uncontrollability and Danger” 
subscale, mean (SD)
17.28 (4.82) 16.98 (4.55)a 15.87 (4.70)
PBEQ: “Negative Appraisals of Experiences” subscale, mean (SD) 14.09 (3.16) 14.22 (3.16)b 12.92 (3.78)
PANSS: positive symptoms, mean (SD) 20.99 (4.89) 20.29 (4.30) 16.63 (6.21)
PANSS: negative symptoms, mean (SD) 14.75 (4.52) 14.73 (4.90) 13.90 (4.48)
PANSS: general symptoms, mean (SD) 36.69 (7.54) 36.02 (7.36) 31.98 (9.34)
PANSS: total symptoms, mean (SD) 72.43 (13.77) 71.04 (13.41) 62.51 (17.44)
BDI-7: suicidal ideation, mean (SD) 0.74 (0.73) 0.73 (0.81) 0.53 (0.71)
BDI-7: suicidal ideation (no ideation), n (%) 27 (40) 22 (45) 28 (57)
BDI-7: suicidal ideation (mild), n (%) 34 (50) 20 (41) 17 (35)
BDI-7: suicidal ideation (moderate to severe), n (%) 5 (7.4) 5 (10) 3 (6)
BDI-7: suicidal ideation (severe), n (%) 2 (3) 2 (4) 1 (2)
Note: SD, standard deviation; MCQ-30, Metacognition Questionnaire-30; PBEQ, Personal Beliefs About Experiences Questionnaire; 
PANSS, Positive and Negative Syndrome Scale; BDI-7, Beck Depression Inventory-7.
aN = 48.
bN = 47.
Table 2. Correlations Between Variables (Pearson’s r, 2-tailed)
Time point 
(mo) N Age Education
MCQ 
negative 
beliefs
PBEQ 
negative 
appraisals
Positive 
symptoms
Negative 
symptoms
General 
symptoms
Overall 
symptoms
Education 0 68 −.02
0 49 −.17
9–18 49 −.17
MCQ 
negative 
beliefs
0 68 −.08 .10
0 48 −.14 −.08
9–18 49 .02 −.12
PBEQ 
negative 
appraisals
0 68 −.17 −.01 .59**
0 47 −.04 −.10 .58**
9–18 49 .12 −.10 .72**
Positive 
symptoms
0 68 .20 −.05 .16 .17
0 47–49 .08a −.06a .30b* .29c*
9–18 49 .23 −.24 .64** .58**
Negative 
symptoms
0 68 −.12 −.21 −.02 .13 .25*
0 47–49 −.16a −.23a .05b .13c .27a
9–18 49 .06 −.13 .15 .31* .39**
General 
symptoms
0 68 −.03 −.04 .37** .42** .60** .49**
0 47–49 −.15a −.03a .40b** .43c** .59a** .48a**
9–18 49 .19 −.04 .63** .58** .78** .56**
Overall 
symptoms
0 68 .01 −.11 .25* .33** .77** .68** .92**
0 47–49 −.12a −.12a .33b* .38c** .74a** .72a** .91a**
9–18 49 .20 −.14 .60** .59** .87** .69** .96**
BDI-7 
suicidal 
ideation
0 68 −.01 −.02 .43** .51** .25* .00 .45** .34**
0 47–49 −.02a −.02a .46b** .51c** .36a* −.02a .45a** .36a*
9–18 49 .11 −.07 .57** .47** .50** .30* .47** .51**
Note: Abbreviations are explained in the first footnote to Table 1.
aN = 49.
bN = 48.
cN = 47.
*P < .05; ** P < .01. All significant results (P < .05) are highlighted in bold.
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and the combined negative cognitive appraisals and neg-
ative metacognitive beliefs pathways (CSE = 0.03, 95% 
CI  =  −0.00, 0.11). No direct (unmediated) effect was 
observed. The same pattern was observed for positive 
symptoms. Overall, the effects suggest a 1 SD increase in 
overall or positive symptoms were indirectly associated 
with small increases in suicidal ideation (CSEs = 0.12–
0.18), with approximately 70% of the indirect effects 
accounted for by the negative cognitive appraisals alone 
pathway, and 20% by the combined negative cognitive 
appraisals and negative metacognitive beliefs pathway. 
Negative symptoms did not have a direct or indirect 
relationship with suicidal ideation. General symptoms 
had both a direct effect on suicidal ideation, suggesting 
a 0.03 unit increase in suicidal ideation scores for each 
unit increase in general symptoms (UDE 0.03, SE 0.012, 
P < .05) and an indirect (mediated) effect (CSE = 0.19, 
95% CI = 0.09, 0.34), suggesting that for a 1 SD increase 
in general symptoms, there was an additional 0.19 SD 
increase in suicidal ideation. As with total and positive 
symptoms, approximately 70% of this was accounted 
for by negative cognitive appraisals (CSE  =  0.14, 95% 
CI = 0.05, 0.26).
The indirect effect of positive symptoms was not 
robust to controlling for negative and general symptoms. 
However, both the direct and indirect effects of general 
symptoms remained significant after controlling for pos-
itive and negative symptoms. Although the overall indi-
rect effect was marginally smaller (CSE  =  0.17, 95% 
CI  =  0.06, 0.31), the proportion explained by negative 
cognitive appraisals was larger (80%) in this analysis.
9–18 Months
No direct effect of total symptom severity on suicidal ide-
ation was observed at 9–18 months; however, this had an 
indirect effect through the combined pathway of negative 
cognitive appraisals and negative metacognitive beliefs 
(CSE = 0.10, 95% CI = −0.00, 0.29) (supplementary table 
S3). For a 1 SD increase in total symptoms, there was an 
overall 0.27 SD (95% CI = 0.06, 0.26) indirect increase 
in suicidal ideation. The combined appraisals and nega-
tive metacognitive beliefs pathway accounted for approx-
imately 37% of this effect. There was also no direct effect 
of positive symptoms. Although they had a significant 
indirect effect on suicidal ideation, with a 1 SD increase 
in positive symptoms indirectly associated with a 0.31 SD 
(95% CI = 0.04, 0.61) increase in suicidal ideation, no one 
individual pathway was significant. The relative contribu-
tions of each individual pathway to this effect was simi-
lar to that for total symptoms. Negative symptoms had a 
direct effect on suicidal ideation at this time point, but no 
indirect effect. For each unit increase in negative symp-
toms, there was a 0.043 unit increase in suicidal ideation 
(SE = 0.021, P < .05). As with total and positive symp-
toms, general symptoms were not directly associated with 
suicidal ideation. As with total symptoms, general symp-
toms had an indirect effect on suicidal ideation via the 
combined appraisals and metacognitive beliefs pathway 
(CSE = 0.10, 95% CI = 0.01, 0.30). The effect sizes and 
relative contribution of individual pathways were similar 
to those for total and positive symptoms.
When we entered other symptom categories as covari-
ates in the analyses of positive, negative, and general 
symptoms, the indirect effects for positive symptoms 
were no longer significant and the analysis of negative 
symptoms remained unchanged. General symptoms con-
tinued to not have a direct effect after controlling for pos-
itive and negative symptoms. The indirect effect remained 
significant; however, the contribution of the individual 
pathways changed, and the total indirect effect fell from 
a 0.32 SD (95% CI = 0.09, 0.58) change in suicidal idea-
tion per 1 SD change in general symptoms to a 0.22 SD 
(95% CI = 0.04, 0.45) change. The contribution of neg-
ative metacognitive beliefs to this effect increased from a 
nonsignificant 49% to a significant 70% (CSE = 0.16, 95% 
CI = 0.01, 0.43), and the contribution of the combined 
appraisals and metacognitive beliefs pathway fell from a 
significant 31% to a nonsignificant 24%.
Longitudinal Analyses
Multiple Linear Regression. Baseline psychotic symp-
toms and suicidal ideation, together with covariates, 
accounted for 54% of the variance in suicidal ideation 
at 9–18 months (supplementary table S2). Adding base-
line negative cognitive appraisals to the model did not 
account for additional variance; however, adding nega-
tive metacognitive beliefs accounted for a further 5% (P 
< .05). An effect of female gender also emerged; this was 
associated with a significant reduction in BDI suicidal 
ideation scores (0.4 point, P < .05).
Mediation Analysis
No direct effects of baseline symptoms on suicidal idea-
tion at 9–18 months were observed (table 3). There were 
also no indirect effects of baseline negative or positive 
symptoms. Baseline total symptoms and general symp-
toms, however, had indirect effects on suicidal ideation at 
follow-up via the combined appraisals and metacognitive 
beliefs pathway. A 1 SD increase in baseline overall symp-
toms and baseline general symptoms accounted for a 0.03 
SD (95% CI = 0.00, 0.12) and 0.04 SD (95% CI = 0.00, 
0.14) increase in suicidal ideation at 9–18 months via this 
pathway, respectively.
The analyses for general, positive, and negative symp-
toms were largely unaffected by controlling for other 
symptom categories, although a significant direct effect 
of baseline negative metacognitive beliefs (UDE = 0.051, 
SE = 0.023, P =  .03) emerged in the general symptoms 
analysis and, as with the linear regression, a significant 
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Table 3. Results of Longitudinal Mediation Analyses 
Model (all n = 47) Predictor
Suicidal ideation in 9- or 18-mo completers
Unstandardized 
coefficients (SE)
Completely standardized 
coefficients (95% CI)
Overall symptoms Control variables Age (baseline), y 0.010 (0.008) —
Gender (fixed) −0.325 (0.170)* —
Education (baseline) −0.013 (0.029) —
Treatment allocation −0.082 (0.168) —
Suicidal ideation at mo 0 0.515 (0.122)*** —
9- or 18-mo data 0.299 (0.200) —
Independent variables Overall symptoms at mo 0 
(direct effect)
0.001 (0.007) —
Negative cognitive 
appraisals at mo 0
−0.022 (0.034) —
Negative metacognitive 
beliefs at mo 0
0.043 (0.023)* —
R2 0.562***
Bootstrap indirect effects 
of
Overall symptoms > 
Negative  
cognitive appraisals
−0.001 (0.002)
95% CI (−0.007, 0.001)
−0.022 (−0.049, 0.253)
Overall symptoms > 
Negative  
metacognitive beliefs
0.002 (0.003)
95% CI (−0.001, 0.011)
0.038 (−0.029, 0.235)
Overall symptoms > 
Negative  
cognitive appraisals > 
Negative  
metacognitive beliefs
0.001** (0.001)
95% CI (0.000, 0.006)
0.028** (0.000, 0.120)
Total indirect effect 0.002 (0.003)
95% CI (−0.002, 0.012)
0.045 (−0.049, 0.253)
Positive symptoms Control variables Age (baseline), y 0.010 (0.008) —
Gender (fixed) −0.354** (0.167)a —
Education (baseline) −0.014 (0.029) —
Treatment allocation −0.067 (0.166) —
Suicidal ideation at mo 0 0.538*** (0.121)a —
9- or 18-mo data 0.308 (0.196) —
Independent variables Positive symptoms at mo 0 
(direct effect)
−0.012 (0.020) —
Negative cognitive 
appraisals at mo 0
−0.020 (0.034) —
Negative metacognitive 
beliefs at mo 0
0.045* (0.023)a —
R2 0.566**a —
Bootstrap indirect effects of Positive symptoms > 
Negative  
cognitive appraisals
−0.002 (0.004)
95% CI (−0.017, 0.002)
−0.013 (−0.135, 0.018)
Positive symptoms > 
Negative  
metacognitive beliefs
0.005 (0.009)
95% CI (−0.005, 0.032)
0.041 (−0.040, 0.231)
Positive symptoms > 
Negative  
cognitive appraisals > 
Negative  
metacognitive beliefs
0.002 (0.004)
95% CI (−0.002, 0.014)
0.019 (−0.013, 0.105)
Total indirect effect 0.006 (0.009)
95% CI (−0.017, 0.002)
0.048 (−0.054, 0.236)
Negative symptoms Control variables Age (baseline), y 0.011 (0.007) —
Gender (fixed) −0.322* (0.161)a —
Education (baseline) −0.005 (0.029) —
Treatment allocation −0.125 (0.167) —
Suicidal ideation at mo 0 0.522*** (0.115)a —
9- or 18-mo data 0.269 (0.194) —
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association between suicidal ideation and female gender 
emerged in each analysis, with a similar effect size.
Discussion
We tested a metacognitive model of suicidal ideation 
in people with psychosis not taking antipsychotic 
medication, a group considered to be at particularly high 
risk of suicide.3,4 We tested whether psychotic symptoms 
may contribute to increased suicidal ideation not only 
directly, but also indirectly via appraisals of symptoms 
and metacognitive beliefs about the probability and con-
sequences of losing mental control.23,24
Model (all n = 47) Predictor
Suicidal ideation in 9- or 18-mo completers
Unstandardized 
coefficients (SE)
Completely standardized 
coefficients (95% CI)
Independent variables Negative symptoms at mo 
0 (direct effect)
0.022 (0.017) —
Negative cognitive 
appraisals at mo 0
−0.024 (0.033) —
Negative metacognitive 
beliefs at mo 0
0.044* (0.022)a —
R2 0.580**a —
Bootstrap indirect effects 
of
Negative symptoms > 
Negative  
cognitive appraisals
−0.001 (0.006)
95% CI (−0.015, 0.002)
−0.009 (−0.118, 0.016)
Negative symptoms > 
Negative  
metacognitive beliefs
−0.001 (0.006)
95% CI (−0.014, 0.011)
−0.013 (−0.125, 0.079)
Negative symptoms > 
Negative  
cognitive appraisals > 
Negative  
metacognitive beliefs
0.001 (0.003)
95% CI (−0.002, 0.011)
0.011 (−0.018, 0.016)
Total indirect effect −0.001 (0.006)
95% CI (−0.012, 0.014)
−0.010 (−0.111, 0.105)
General symptoms Control variables Age (baseline), y 0.009 (0.008) —
Gender (fixed) −0.347* (0.173)a —
Education (baseline) −0.014 (0.029) —
Treatment allocation −0.075 (0.166) —
Suicidal ideation at mo 0 0.531*** (0.125)a —
9- or 18-mo data 0.318 (0.203) —
Independent variables General symptoms at mo 0 
(direct effect)
−0.004 (0.014) —
Negative cognitive 
appraisals at mo 0
−0.020 (0.034) —
Negative metacognitive 
beliefs at mo 0
0.044* (0.023)a —
R2 0.562**a —
Bootstrap indirect effects of General symptoms > 
Negative  
cognitive appraisals
−0.002 (0.004)
95% CI (−0.015, 0.003)
−0.025 (−0.171, 0.035)
General symptoms > 
Negative  
metacognitive beliefs
0.005 (0.006)
95% CI (−0.001, 0.023)
0.061 (−0.019, 0.248)
General symptoms > 
Negative  
cognitive appraisals > 
Negative  
metacognitive beliefs
0.003** (0.002)a
95% CI (0.000, 0.013)
0.035** (0.004, 0.141)
Total indirect effect 0.006 (0.007)a
95% CI (−0.031, 0.024)
0.071 (−0.044, 0.279)
Note: Exact P values for completely standardized indirect effects not available. Significance (P < .05) inferred when 95% confidence 
intervals exclude zero.
aRemained or became significant (P < .05) after entering other symptom groups as covariates.
*P < .1, **P < .05, ***P < .01.All significant results (P < .05) are highlighted in bold.
Table 3. Continued
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We found no evidence that positive or total symptom se-
verity has a direct effect on suicidal ideation in this group. 
Only concurrent general symptoms had a direct effect at 
baseline, and only concurrent negative symptoms had a 
direct effect at follow-up. Concurrent general symptoms 
also had an indirect effect on baseline suicidal ideation, 
mediated by negative cognitive appraisals. This was robust 
to controlling for other symptom categories. However 
no indirect effect of negative symptoms was found, and 
the indirect effect of positive symptoms was not robust 
to controlling for general and negative symptoms. At 
9–18 months, a similar pattern emerged. However, nega-
tive metacognitive beliefs played a more significant role at 
this point, which suggests the psychological mechanisms 
involved in suicidal ideation in psychosis may change 
over time in this group. They either formed part of the 
indirect pathway, mediating the mediating effect of nega-
tive cognitive appraisals (positive symptoms and general 
symptoms), or were a sole mediator (general symptoms 
controlling for positive and negative symptoms). Again, 
the pathway linking general symptoms and suicidal idea-
tion was the only indirect pathway robust to controlling 
for other symptom categories.
The longitudinal analyses are relevant to interpreting 
these findings. No direct effect of baseline general symp-
toms on later suicidal ideation was evident, but it had an 
indirect effect through concurrently measured negative 
cognitive appraisals and negative metacognitive beliefs. 
Although this indirect pathway explained only a very 
small amount of future suicidal ideation, both the linear 
regression and the mediation analyses (general symptoms, 
controlling for negative and positive symptoms) suggested 
a 1-point increase in baseline negative metacognitive 
beliefs may directly account for a 0.05-point increase in 
suicidal ideation at 9–18 months, which corresponds to a 
0.5-point increase on the BDI suicide item (scored 0–3) per 
10-point increase in negative metacognitive beliefs (scored 
6–24). Notably, these beliefs did not predict concurrent 
suicidal ideation at baseline. If further research confirms 
these findings, high negative metacognitive beliefs at base-
line may be a useful predictor of later increases in suicidal 
ideation in people with psychosis who are not currently 
taking antipsychotic medication, both directly and as a 
mediator of early general symptoms.
Limitations
We used a single-item measure of suicidal ideation; how-
ever, Desseilles et al.50, in a study of 281 suicide attempt-
ers, concluded the single suicide item represented a valid 
approach to assess suicidal ideation, a finding replicated 
by Brown and colleagues51 in a sample of 5319 patients. 
Endorsing suicidal ideation on the BDI item also has 
important implications for clinical risk assessment.51 The 
BDI data were treated as interval for the analyses. This is 
in line with previous studies,45–48 and dichotomizing the 
data for logistic regression would incur a substantial loss 
of statistical power.52,53 There is debate over the best way 
to conceptualize questionnaire data,54 but we encourage 
attempts to replicate these findings using full-scale meas-
ures (eg, the Beck Scale for Suicidal Ideation55). Evidence 
suggests the PANSS may have a 5-factor structure.56,57 We 
used the traditional 3-factor structure,34 because this is 
widely used and interpretable by clinicians.58 Although a 
larger sample would have greater power to detect smaller 
effects with greater precision, in-depth psychological 
studies of people with psychosis who are antipsychotic-
free are rare, partly because few people with psychosis are 
not taking antipsychotics. Finally, the analyses tested a 
theoretically driven model, but alternative ordering of the 
variables is also plausible. Causal claims await the results 
of randomized controlled “interventionist-causal” tri-
als,59 where the effect of selectively reduce negative meta-
cognitive beliefs on suicidality can be assessed.
Implications
Consistent with previous findings, that fears of mental dis-
integration are strongly associated with suicide in psycho-
sis,3 our results suggest that the way people appraise their 
symptoms and their consequences, including whether they 
heighten concerns about losing mental control, may partly 
determine whether they lead to thoughts of suicide. RCTs 
of interventions that either address negative metacognitive 
beliefs, such as MCT,18 or directly enhance self-integration, 
such as Metacognitive Reflection and Insight Therapy60 
and Cognitive Analytic Therapy,61,62 may be warranted 
to examine their effect on suicidality. Overall, our find-
ings emphasize the importance of clinicians promoting 
a recovery-focused and appropriately optimistic outlook 
when working with people with psychosis, taking care to 
avoid providing information that might heighten negative 
illness appraisals and/or fears of losing mental control.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
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